Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 770

1.

Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?

Jain RK, Grivas P, Pal SK.

BJU Int. 2019 Sep;124(3):361-362. doi: 10.1111/bju.14877. No abstract available.

2.

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.

Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI.

Lancet Oncol. 2019 Aug 16. pii: S1470-2045(19)30513-3. doi: 10.1016/S1470-2045(19)30513-3. [Epub ahead of print]

PMID:
31427205
3.

Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Graham J, Wells JC, Donskov F, Lee JL, Fraccon A, Pasini F, Porta C, Bowman IA, Bjarnason GA, Ernst DS, Rha SY, Beuselinck B, Hansen A, North SA, Kollmannsberger CK, Wood LA, Vaishampayan UN, Pal SK, Choueiri TK, Heng DYC.

Eur Urol Oncol. 2019 Apr 4. pii: S2588-9311(19)30041-0. doi: 10.1016/j.euo.2019.03.007. [Epub ahead of print]

PMID:
31411994
4.

Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC; RISC Investigators.

Eur Urol Oncol. 2019 Jan 30. pii: S2588-9311(19)30001-X. doi: 10.1016/j.euo.2018.12.013. [Epub ahead of print]

PMID:
31411990
5.

Improvement of Photostability and NIR Activity of Cyanine Dye through Nanohybrid Formation: Key Information from Ultrafast Dynamical Studies.

Bera A, Bagchi D, Pal SK.

J Phys Chem A. 2019 Aug 22. doi: 10.1021/acs.jpca.9b04100. [Epub ahead of print]

PMID:
31402654
6.

Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients.

Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N.

J Geriatr Oncol. 2019 Aug 8. pii: S1879-4068(19)30128-6. doi: 10.1016/j.jgo.2019.07.002. [Epub ahead of print] No abstract available.

PMID:
31402176
7.

Association between chemotherapy toxicity risk scores and physical symptoms among older Brazilian adults with cancer.

Bergerot CD, Razavi M, Philip EJ, Bergerot PG, Soto-Perez-de-Celis E, De Domenico EBL, Clark KL, Loscalzo M, Pal SK, Dale W.

J Geriatr Oncol. 2019 Aug 8. pii: S1879-4068(19)30191-2. doi: 10.1016/j.jgo.2019.07.006. [Epub ahead of print]

PMID:
31401205
8.

Identifying Drug Resistant miRNAs using Entropy Based Ranking.

Pal JK, Ray SS, Pal SK.

IEEE/ACM Trans Comput Biol Bioinform. 2019 Aug 6. doi: 10.1109/TCBB.2019.2933205. [Epub ahead of print]

PMID:
31398129
9.

Association Between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies: A Systematic Review and Meta-Analysis.

Wallis CJD, Satkunasivam R, Butaney M, Khan UA, Goldberg HA, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

Am J Clin Oncol. 2019 Jul 19. doi: 10.1097/COC.0000000000000577. [Epub ahead of print]

PMID:
31335350
10.

Correction to "Liquid Crystal based Detection of Pb(II) Ions Using Spinach RNA as Recognition Probe".

Verma I, Devi M, Sharma D, Nandi R, Pal SK.

Langmuir. 2019 Jul 30;35(30):9994. doi: 10.1021/acs.langmuir.9b02053. Epub 2019 Jul 19. No abstract available.

PMID:
31322354
11.

Different roles of peroxisome proliferator-activated receptor gamma isoforms in prostate cancer.

Salgia MM, Elix CC, Pal SK, Jones JO.

Am J Clin Exp Urol. 2019 Jun 15;7(3):98-109. eCollection 2019.

12.

Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How.

Pal SK, Swami U, Agarwal N.

Eur Urol. 2019 Jul 9. pii: S0302-2838(19)30519-6. doi: 10.1016/j.eururo.2019.06.029. [Epub ahead of print] No abstract available.

PMID:
31300236
13.

Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges.

Swami U, Pal SK, Agarwal N.

JAMA Oncol. 2019 Jun 27. doi: 10.1001/jamaoncol.2019.1008. [Epub ahead of print] No abstract available.

PMID:
31246246
14.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.

Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00283. Epub 2019 May 10.

15.

Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.

Martini A, Jia R, Ferket BS, Waingankar N, Plimack ER, Crabb SJ, Harshman LC, Yu EY, Powles T, Rosenberg JE, Pal SK, Vaishampayan UN, Necchi A, Wiklund NP, Mehrazin R, Mazumdar M, Sfakianos JP, Galsky MD.

Cancer. 2019 May 31. doi: 10.1002/cncr.32169. [Epub ahead of print]

PMID:
31150110
16.

Liquid Crystal based Detection of Pb(II) Ions Using Spinach RNA as Recognition Probe.

Verma I, Devi M, Sharma D, Nandi R, Pal SK.

Langmuir. 2019 Jun 18;35(24):7816-7823. doi: 10.1021/acs.langmuir.8b04018. Epub 2019 May 30. Erratum in: Langmuir. 2019 Jul 30;35(30):9994.

PMID:
31117720
17.

Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?

Larcher A, Wallis CJD, Bex A, Blute ML, Ficarra V, Mejean A, Karam JA, Van Poppel H, Pal SK.

Eur Urol Oncol. 2019 Jul;2(4):365-378. doi: 10.1016/j.euo.2019.04.007. Epub 2019 May 18. Review.

PMID:
31109902
18.

Exciton dissociation in an NIR-active triohybrid nanocrystal leading to efficient generation of reactive oxygen species.

Patwari J, Joshi H, Mandal H, Roy L, Bhattacharya C, Lemmens P, Pal SK.

Phys Chem Chem Phys. 2019 May 28;21(20):10667-10676. doi: 10.1039/c9cp01923e. Epub 2019 May 14.

PMID:
31086863
19.

Modulation of Kinetic Pathways of Enzyme-Substrate Interaction in a Microfluidic Channel: Nanoscopic Water Dynamics as a Switch.

Singh P, Mukherjee D, Singha S, Das R, Pal SK.

Chemistry. 2019 Jul 22;25(41):9728-9736. doi: 10.1002/chem.201901751. Epub 2019 Jun 28.

PMID:
31062438
20.

Generation of orthogonal lattice fields.

Pal SK, Senthilkumaran P.

J Opt Soc Am A Opt Image Sci Vis. 2019 May 1;36(5):853-858. doi: 10.1364/JOSAA.36.000853.

PMID:
31045013
21.

In situ measurement of temperature dependent picosecond resolved carrier dynamics in near infrared (NIR) sensitive device on action.

Patwari J, Chatterjee A, Ghadi H, Sharma H, Chakrabarti S, Pal SK.

Rev Sci Instrum. 2019 Apr;90(4):043909. doi: 10.1063/1.5050951.

PMID:
31042972
22.

Structural Understanding, Photoswitchability, and Supergelation of a New Class of Four Ring-Based Bent-Shaped Liquid Crystal.

Begum N, Kaur S, Mohiuddin G, Nandi R, Gupta SP, Rao NVS, Pal SK.

J Phys Chem B. 2019 May 23;123(20):4443-4451. doi: 10.1021/acs.jpcb.9b01456. Epub 2019 May 10.

PMID:
31042387
23.

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.

Pal SK, Moreira D, Won H, White SW, Duttagupta P, Lucia M, Jones J, Hsu J, Kortylewski M.

Int J Mol Sci. 2019 Apr 13;20(8). pii: E1831. doi: 10.3390/ijms20081831.

24.

Hexagonal vector field of polarization singularities with a gradient basis structure.

Pal SK, Senthilkumaran P.

Opt Lett. 2019 Apr 15;44(8):2093-2096. doi: 10.1364/OL.44.002093.

PMID:
30985819
25.

Effectiveness and Safety of Metformin versus Canthex™ in Patients with Acanthosis Nigricans: A Randomized, Double-blind Controlled Trial.

Sett A, Pradhan S, Sancheti K, Basu D, Datta A, Biswas L, Das S, Pal SK, Gupta N, Sil A, Das NK.

Indian J Dermatol. 2019 Mar-Apr;64(2):115-121. doi: 10.4103/ijd.IJD_417_17.

26.

The Changing Landscape of Management of Metastatic Renal Cell Carcinoma: Current Treatment Options and Future Directions.

Salgia NJ, Dara Y, Bergerot P, Salgia M, Pal SK.

Curr Treat Options Oncol. 2019 Apr 1;20(5):41. doi: 10.1007/s11864-019-0638-1. Review.

PMID:
30937639
27.

Postsynthesis Spontaneous Coalescence of Mixed-Halide Perovskite Nanocubes into Phase-Stable Single-Crystalline Uniform Luminescent Nanowires.

Pradhan B, Mushtaq A, Roy D, Sain S, Das B, Ghorai UK, Pal SK, Acharya S.

J Phys Chem Lett. 2019 Apr 18;10(8):1805-1812. doi: 10.1021/acs.jpclett.9b00832. Epub 2019 Apr 2.

PMID:
30929427
29.

Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium.

Pal SK, Tew BY, Lim M, Stankavich B, He M, Pufall M, Hu W, Chen Y, Jones JO.

ACS Omega. 2019 Feb 28;4(2):2472-2481. doi: 10.1021/acsomega.8b03205. Epub 2019 Feb 1.

30.

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy.

Bergerot CD, Bergerot PG, Philip EJ, Hsu JA, Dizman N, Vaishampayan U, Dorff T, Pal SK.

J Immunother Cancer. 2019 Mar 12;7(1):71. doi: 10.1186/s40425-019-0557-5.

31.

Examining Public Communication About Kidney Cancer on Twitter.

Sedrak MS, Salgia MM, Decat Bergerot C, Ashing-Giwa K, Cotta BN, Adashek JJ, Dizman N, Wong AR, Pal SK, Bergerot PG.

JCO Clin Cancer Inform. 2019 Mar;3:1-6. doi: 10.1200/CCI.18.00088.

32.

Patient-reported Outcome Measures in Metastatic Urinary Cancers.

Bergerot CD, Bergerot PG, Philip EJ, Pal SK.

Eur Urol Focus. 2019 Mar 8. pii: S2405-4569(19)30055-0. doi: 10.1016/j.euf.2019.02.020. [Epub ahead of print] Review.

PMID:
30858072
33.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC.

Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28.

PMID:
30827746
34.

Unraveling the Role of Monoolein in Fluidity and Dynamical Response of a Mixed Cationic Lipid Bilayer.

Singh P, Sharma VK, Singha S, García Sakai V, Mukhopadhyay R, Das R, Pal SK.

Langmuir. 2019 Apr 2;35(13):4682-4692. doi: 10.1021/acs.langmuir.9b00043. Epub 2019 Mar 12.

PMID:
30807692
35.

Genetic diversity and matrilineal genetic origin of fat-rumped sheep in Ethiopia.

Nigussie H, Mwacharo JM, Osama S, Agaba M, Mekasha Y, Kebede K, Abegaz S, Pal SK.

Trop Anim Health Prod. 2019 Jul;51(6):1393-1404. doi: 10.1007/s11250-019-01827-z. Epub 2019 Feb 24.

PMID:
30798433
36.

Editorial Comment.

Salgia NJ, Pal SK.

J Urol. 2019 Mar;201(3):548. doi: 10.1097/01.JU.0000553713.64297.bb. No abstract available.

PMID:
30759699
37.

Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma.

Bergerot CD, Battle D, Bergerot PG, Dizman N, Jonasch E, Hammers HJ, George DJ, Bex A, Ljungberg B, Pal SK, Staehler MD.

Front Oncol. 2019 Jan 22;9:11. doi: 10.3389/fonc.2019.00011. eCollection 2019.

38.

Room-Temperature Columnar Liquid Crystals as Efficient Pure Deep-Blue Emitters in Organic Light-Emitting Diodes with an External Quantum Efficiency of 4.0.

De J, Yang WY, Bala I, Gupta SP, Yadav RAK, Dubey DK, Chowdhury A, Jou JH, Pal SK.

ACS Appl Mater Interfaces. 2019 Feb 27;11(8):8291-8300. doi: 10.1021/acsami.8b18749. Epub 2019 Feb 14.

PMID:
30707013
39.

Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE.

J Clin Oncol. 2019 Apr 1;37(10):834-849. doi: 10.1200/JCO.18.02037. Epub 2019 Jan 31. No abstract available.

PMID:
30702028
40.

Gold nanoparticle-mediated signal amplification of liquid crystal biosensors for dopamine.

Nandi R, Loitongbam L, De J, Jain V, Pal SK.

Analyst. 2019 Feb 21;144(4):1110-1114. doi: 10.1039/c8an02171f. Epub 2019 Jan 28.

PMID:
30687868
41.

Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.

Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Nachaegari G, Harwood D, Agarwal N.

Cancer Treat Res Commun. 2019;19:100116. doi: 10.1016/j.ctarc.2018.100116. Epub 2018 Dec 20.

PMID:
30682445
42.

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.

Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N.

PLoS One. 2019 Jan 25;14(1):e0210415. doi: 10.1371/journal.pone.0210415. eCollection 2019.

43.

The Microbiome and Genitourinary Cancer: A Collaborative Review.

Markowski MC, Boorjian SA, Burton JP, Hahn NM, Ingersoll MA, Maleki Vareki S, Pal SK, Sfanos KS.

Eur Urol. 2019 Apr;75(4):637-646. doi: 10.1016/j.eururo.2018.12.043. Epub 2019 Jan 15. Review.

PMID:
30655087
44.

Synthesis of Stokes vortices.

Pal SK, Senthilkumaran P.

Opt Lett. 2019 Jan 1;44(1):130-133. doi: 10.1364/OL.44.000130.

PMID:
30645560
45.

A Novel Whole Spectrum-based Non-invasive Screening Device for Neonatal Hyperbilirubinemia.

Halder A, Banerjee M, Singh S, Adhikari A, Sarkar PK, Bhattacharya AM, Chakrabarti P, Bhattacharyya D, Mallick AK, Pal SK.

IEEE J Biomed Health Inform. 2019 Jan 14. doi: 10.1109/JBHI.2019.2892946. [Epub ahead of print]

PMID:
30640639
46.

A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.

Pal SK, Forero-Torres A, Thompson JA, Morris JC, Chhabra S, Hoimes CJ, Vogelzang NJ, Boyd T, Bergerot PG, Adashek JJ, Li H, Yu X, Gartner EM, Carret AS, Smith DC.

Cancer. 2019 Apr 1;125(7):1124-1132. doi: 10.1002/cncr.31912. Epub 2019 Jan 9.

PMID:
30624766
47.

Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.

Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8.

PMID:
30620391
48.

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.

Wallis CJD, Butaney M, Satkunasivam R, Freedland SJ, Patel SP, Hamid O, Pal SK, Klaassen Z.

JAMA Oncol. 2019 Apr 1;5(4):529-536. doi: 10.1001/jamaoncol.2018.5904.

PMID:
30605213
49.

Tumor mutational burden and response to programmed cell death protein 1 inhibitors in a case series of patients with metastatic desmoplastic melanoma.

Boussemart L, Johnson A, Schrock AB, Pal SK, Frampton GM, Fabrizio D, Chalmers Z, Lotem M, Gibney G, Russell J, Chmielowski B, Ross JS, Stephens PJ, Miller VA, Ali SM.

J Am Acad Dermatol. 2019 Jun;80(6):1780-1782. doi: 10.1016/j.jaad.2018.12.020. Epub 2018 Dec 18. No abstract available.

50.

Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial.

Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, Agarwal N.

Oncologist. 2018 Dec;23(12):1413-e151. doi: 10.1634/theoncologist.2018-0652. Epub 2018 Nov 1.

Supplemental Content

Support Center